Related Experiment Video
Updated: Jan 12, 2026

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying
Sara E Boyd1,2,3, Mandy Wootton4, Robin A Howe4
1David Price Evans Global Health and Infectious Disease Research Group, University of Liverpool, Institute of Systems, Molecular & Integrative Biology, William Henry Duncan Building, Liverpool L7 8TX, UK.
Abstract:
EUCAST introduced 'breakpoints in brackets' to warn against the use of specified agents without additional therapeutic measures (EUCAST. Guidance document "EUCAST breakpoints in brackets". 2021. Available at: www.mic.eucast.org.). Rifampicin is rarely used as monotherapy for Staphylococcus aureus infections, yet its breakpoints remain unbracketed. Here, we explore whether this remains appropriate. Although frequent emergent resistance largely precludes rifampicin's use as monotherapy, this does not meet EUCAST's core criterion for bracketing-that an agent is inherently ineffective as monotherapy.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

